News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

NICE has recommended moving Novartis’ Kisqali (ribociclib) from interim funding arrangements to regular NHS reimbursement for certain previously treated breast cancer patients. In the final ...

In May 2024, Google DeepMind released AlphaFold 3, a game changing protein folding model that predicts with 50% better ...

Ibrance failed the PALLAS trial as adjuvant treatment for early breast cancer, giving Verzenio its ... catch-up in the category with Novartis’ Kisqali (ribociclib), which got a green light ...

Drugs that act against this target include Ibrance (palbociclib) and Kisqali (ribociclib), both of which are given alongside hormone therapies. A third new target for breast cancer treatment is the ...

A small clinical trial shows promising results for patients with triple-negative breast cancer who received an ...

A small clinical trial shows promising results for patients with triple-negative breast cancer who received an investigational vaccine designed to prevent recurrence of tumors.

American Cancer Society research shows despite significant drops in the mortality rate, breast cancer incidence rates have ...

In this on-demand webinar series, CURE partnered with UCLA Health and Northside Hospital Cancer Institute to discuss best ...

Under this two-hit model, Brugge says, one normal copy of BRCA1 ought to be able to carry out DNA repair even when the other copy is inactivated by an inherited mutation. This means that a total loss ...

A 50-year-old scientist, Beata Halassy, treated her own stage 3 breast cancer by injecting the tumour with lab-grown viruses.

Mitochondria have long been known as the tiny organelles that act as the battery packs inside our cells while also serving as internal sensors and communicators.